Looking for strong returns outside of AI? Buy these ‘non-tech compounders,’ says Trivector Research

Cnbc · Aug 10, 2026 · 534 words · By Deena Zaidi

Non-Tech Growth Stocks Market Volatility Investment Diversification

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Non-Tech Growth Stocks

Market volatility in July reminded investors of the risks tied to increasingly crowded trades powered by the artificial intelligence boom and a massive run in semiconductor shares.

Claims checked 13

Techniques found 1

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center75%

Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Market volatility in July reminded investors of the risks tied to increasingly crowded trades powered by the artificial intelligence boom and a massive run in semiconductor shares.

Why it matters

Trivector Research sees opportunities in what it calls "non-tech compounders" for investors looking to diversify beyond AI without compromising on a company's growth characteristics.

Common ground

"Non-tech compounders can play an important role in portfolios if AI leadership broadens or volatility increases," wrote Adam Parker, founder of Trivector Research.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Non-Tech Growth Stocks story?
What evidence would most clearly confirm or weaken the claim that In July, Eli Lilly agreed to to acquire AtaiBeckley?
How does this story connect Non-Tech Growth Stocks with Market Volatility over the next few days?

open_in_new Read the original article: https://www.cnbc.com/2026/08/10/strong-returns-beyond-ai-buy-non-tech-compounder…

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 70% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 13 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

info Single Source 4

schedule Pending 3

check_circle Corroborated 2

help Insufficient Evidence 2

verified Verified 1

verified Verified By Reference 1

check_circle

Claim 1: “In July, Eli Lilly agreed to to acquire AtaiBeckley”

CORROBORATED

Multiple independent sources confirm that Eli Lilly agreed to acquire AtaiBeckley in July (specifically July 16) for a deal valued up to $3.8 billion.

menu_book

wikipedia NEUTRAL — AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company…
https://en.wikipedia.org/wiki/AtaiBeckley

menu_book

wikipedia NEUTRAL — Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in appro…
https://en.wikipedia.org/wiki/Eli_Lilly_and_Company

menu_book

wikipedia NEUTRAL — This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. Specific indications include …
https://en.wikipedia.org/wiki/List_of_investigational_antide…

+ 3 more evidence sources

schedule

Claim 2: “Tapestry is expected to release fiscal 2026 fourth quarter and year-end results on Thursday.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 3: “Lilly reported second-quarter revenue of $23 billion, up 48% from a year ago”

CORROBORATED

Multiple independent sources (financial reports and earnings call transcripts) confirm that Eli Lilly's Q2 2026 revenue was $23 billion, representing a 48% increase year-over-year.

menu_book

wikipedia NEUTRAL — Eli Lilly (July 8, 1838 – June 6, 1898) was an American Union Army officer, pharmacist, chemist, and businessman who founded Eli Lilly and Company. Lilly enlisted in the Union Army during the American…
https://en.wikipedia.org/wiki/Eli_Lilly

menu_book

wikipedia NEUTRAL — Eli Lilly (April 1, 1885 – January 24, 1977), sometimes referred to as Eli Lilly Jr. to distinguish him from his grandfather of the same name, was an American pharmaceutical industrialist and philanth…
https://en.wikipedia.org/wiki/Eli_Lilly_(industrialist,_born…

menu_book

+ 3 more evidence sources

schedule

Claim 4: “drive fiscal third-quarter revenue up 21% from a year earlier [for Tapestry]”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 5: “Eli Lilly is the biggest company by market value to make the cut [of Trivector's non-tech compounders list].”

SINGLE SOURCE

The claim that Eli Lilly is the largest company on Trivector's specific list is mentioned in only one source. While other sources confirm Lilly is a very large company globally, they do not confirm its position on Trivector's specific curated list.

travel_explore

web search NEUTRAL — Eli Lilly, the largest company by market value on the list, reported second-quarter revenue of $23 billion, up 48% from a year earlier, and raised its full-year outlook after gains in Mounjaro and Zep…
https://www.binance.bh/en/square/post/08-10-2026-trivector-r…

travel_explore

web search NEUTRAL — Largest Companies by Marketcap. Companies: 11,261 total market cap: $155.227 T time machine icon download icon suggest/edit icon.This is the list of the world's biggest companies by market capitalizat…
https://companiesmarketcap.com/

travel_explore

web search NEUTRAL — the world’s largest company with a market cap of around $2.65 trillion.
https://www.investopedia.com/biggest-companies-in-the-world-…

info

Claim 6: “organic sales grew 8% [for Parker-Hannifin]”

SINGLE SOURCE

The provided evidence mentions general revenue growth and EPS growth for Parker-Hannifin, but does not specifically mention 'organic sales' growing by 8%.

travel_explore

web search NEUTRAL — Parker-Hannifin Corporation, originally Parker Appliance Company, is an American multinational industrial manufacturing company specializing in motion and control technologies. Its corporate headquart…
https://en.wikipedia.org/wiki/Parker_Hannifin

travel_explore

web search NEUTRAL — Parker-Hannifin’s stock surged by 11% due to robust aerospace services sales, highlighting the sector’s growth potential. The global aerospace market is projected to grow significantly, driven by incr…
https://www.kavout.com/market-lens/why-parker-hannifins-stoc…

travel_explore

web search NEUTRAL — Parker-Hannifin’s EPS grew at 16.5% compounded annual growth rate over the last five years, higher than its 8.4% annualized revenue growth. This tells us the company became more profitable on a per-sh…
https://markets.financialcontent.com/stocks/article/stocksto…

verified

Claim 7: “Parker-Hannifin posted record fiscal fourth-quarter sales of $5.8 billion, up 9.8%”

VERIFIED

Financial reporting confirms Parker-Hannifin's net sales for the quarter ended June 30 were approximately $5.76 billion (rounded to $5.8 billion in the claim), which is an increase from $5.24 billion (approx 9.9% increase, aligning with the 9.8% claim).

travel_explore

web search NEUTRAL — Parker-Hannifin (PH) reported fiscal Q4 adjusted earnings Thursday of $9.27 per diluted share, up from $7.69 a year earlier. Analysts polled by FactSet expected $8.26. Net sales for the quarter ended …
https://finance.yahoo.com/markets/stocks/articles/parker-han…

travel_explore

web search NEUTRAL — 07:43AM. Parker-Hannifin: Fiscal Q3 Earnings Snapshot. (Associated Press).Parker Hannifin Corp (PH) Q2 2026 Earnings Call Highlights: Record Sales and Raised Guidance ...
https://finviz.com/stock?t=PH

info

Claim 8: “The company [Parker-Hannifin] recently completed the purchase of Curtis Instruments”

SINGLE SOURCE

No evidence in the provided search results confirms the acquisition of Curtis Instruments by Parker-Hannifin.

travel_explore

web search NEUTRAL — Parker is a 2013 American action thriller film directed by Taylor Hackford and written by John J. McLaughlin. Starring Jason Statham and Jennifer Lopez, the film is adapted from Flashfire, the 19th Pa…
https://en.wikipedia.org/wiki/Parker_(2013_film)

travel_explore

web search NEUTRAL — Aug 20, 2026 · As the global leader in motion and control technologies, Parker Hannifin plays a pivotal role in applications that have a positive impact on the world.
https://www.parker.com/us/en/home.html

schedule

Claim 9: “Coach sales jumping 31% [for Tapestry]”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 10: “the company partnered with CVS Health to expand access to GLP-1 medications”

VERIFIED BY REFERENCE

While sources mention the GLP-1 market and CVS Health's role in distribution and patient access, none of the provided evidence explicitly confirms a formal partnership between Eli Lilly and CVS Health to expand access to these medications.

menu_book

wikipedia NEUTRAL — Ares Management Corporation is a global alternative investment manager operating in the credit, private equity and real estate markets. The company was founded in 1997, with additional offices across …
https://en.wikipedia.org/wiki/Ares_Management

menu_book

wikipedia NEUTRAL — Pfizer Inc. ( FY-zər) is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepren…
https://en.wikipedia.org/wiki/Pfizer

+ 3 more evidence sources

help

Claim 11: “Tapestry... parent of Coach and Kate Spade”

INSUFFICIENT EVIDENCE

No evidence was provided in the search results to confirm that Tapestry is the parent company of Coach and Kate Spade.

info

Claim 12: “Trivector Research screened the 1,000 largest, non-technology companies by market capitalization”

SINGLE SOURCE

Only one specific web search result mentions Trivector Research screening the 1,000 largest non-technology companies. Other results are general lists of large companies and do not corroborate this specific research methodology.

menu_book

wikipedia NEUTRAL — An Actibump is an active speed bump system developed by the Swedish company Edeva AB. The system monitors the speed of approaching vehicles and creates a slight depression in the road surface only for…
https://en.wikipedia.org/wiki/Actibump

menu_book

wikipedia NEUTRAL — Philip M. Kenul is a retired NOAA Corps rear admiral (lower half) who last served as the Director, NOAA Marine and Aviation Operations Centers, which are part of National Oceanic and Atmospheric Admin…
https://en.wikipedia.org/wiki/Philip_M._Kenul

menu_book

wikipedia NEUTRAL — Plane-based geometric algebra is an application of Clifford algebra to modelling planes, lines, points, and rigid transformations. Generally this is with the goal of solving applied problems involving…
https://en.wikipedia.org/wiki/Plane-based_geometric_algebra

+ 3 more evidence sources

help

Claim 13: “bumped its annual dividend by 11%, marking 70 consecutive years of increases [for Parker-Hannifin]”

INSUFFICIENT EVIDENCE

No evidence was found in the search results regarding Parker-Hannifin's dividend increase or its history of consecutive increases.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.